Bachem stock gains as investors digest strong half-year figures

Bachem stock (ISIN CH0012530207) traded around the mid-70s Swiss francs on the SIX Swiss Exchange on September 18, 2026, after posting recent gains on the back of its latest reported figures for the first half of 2026. As of the late morning session on September 18, 2026, the shares were quoted near 78.70 CHF, reflecting a modest daily increase and continued investor interest.

Half-year 2026 results show double-digit growth

According to Bachem, the company reported its most recent half-year 2026 results with continued growth in its peptide and oligonucleotide business, giving investors a clearer picture of operating momentum in the current year. In the first half of 2026, Bachem generated revenue in the low hundreds of millions of Swiss francs, marking a double-digit percentage increase compared with the same period of 2025 and underlining sustained demand from pharmaceutical and biotech customers in both innovator and generic segments. The company also reported a positive operating result for the period, with earnings before interest and taxes rising faster than revenue, which points to efficiency gains and an improved cost structure in core manufacturing and development activities.

While the exact margin figures for the half-year 2026 period are detailed in the company report, the overarching message is that profitability improved as scale effects kicked in. According to Bachem, management confirmed its guidance for full-year 2026, which calls for continued revenue growth and a further increase in profitability compared with 2025. For investors, the fact that half-year revenue growth is already running in double digits, while operating profit grows at a higher rate, is a key confirmation of the long-term investment case in specialized peptide manufacturing.

Stock extends recent gains on SIX Swiss Exchange

The positive fundamental backdrop is reflected in the share price. In SIX SX trading on September 18, 2026, Bachem stock was among the gainers in the Swiss Performance Index, advancing by about 1.0 percent to 78.70 CHF in late morning activity. In intraday trading, the stock reached a session high of 78.95 CHF after opening at 78.15 CHF, which shows that buyers were willing to pay slightly higher prices as the session progressed. According to finanzen.ch, the stock gained around 0.59 percent in the morning, underlining the steady upward trend.

The current price also needs to be seen in the context of the 52-week range. Over the past 12 months, Bachem shares traded between the low 60s CHF at the bottom of the range and close to the mid-80s CHF at the top, meaning that the September 18, 2026 quote around 78.70 CHF sits noticeably below the 52-week high but well above the 52-week low. From an investor perspective, this positioning suggests that much of the recent recovery has already taken place, yet there remains potential upside if the company can deliver on its guidance and sustain margin improvement.

Analysts highlight growth potential and risks

On the analyst side, current coverage focuses on Bachem's role as a key contract manufacturer for complex peptides and related molecules, as well as the cyclical nature of demand from the biotech and pharmaceutical sector. Recent analyst notes, published in mid-September 2026, point to double-digit revenue growth in half-year 2026 and improving earnings as the main drivers behind their constructive view. At the same time, they flag concentration risks in the customer base and the potential impact of regulatory changes or project delays on short-term revenue volatility.

According to Bachem, the company expects demand in its pipeline of custom manufacturing projects to remain robust for the remainder of 2026, supported by a healthy mix of development-stage and commercial products. Analysts also stress that Bachem's strategic investments in capacity and technology made in 2024 and 2025 are now feeding through into higher volumes and better operating leverage, which explains why earnings growth in the first half of 2026 is outpacing revenue growth.

Next dates and what investors watch now

Looking ahead, investors are already focusing on the next reporting date in the Bachem financial calendar. According to Bachem, the company plans to release its next set of results later in 2026, which will provide updated revenue and margin figures and confirm whether the current positive trend has continued into the second half of the year. For shareholders, this upcoming checkpoint will be crucial to validate the current valuation, as the share price near 78.70 CHF already builds in expectations of sustained growth.

In addition to financial results, investors are watching for new contract announcements, capacity expansion updates and potential regulatory developments affecting peptide-based therapeutics. Bachem's exposure to global pharmaceutical markets means that macroeconomic conditions, healthcare spending trends and the pace of clinical development in partner pipelines can influence order visibility and project timing.

Stock price snapshot and investor takeaway

Based on recent trading data, Bachem stock closed the previous SIX SX session near the mid- to high-70s CHF, with the September 18, 2026 intraday quote of 78.70 CHF marking a modest gain compared with the prior close in the 78.10 CHF area. The move leaves the shares roughly mid-way between the 52-week low in the low 60s CHF and the 52-week high in the mid-80s CHF, highlighting a recovery from earlier weakness but no new high. For investors, the key question is whether double-digit revenue growth in half-year 2026 and stronger earnings will translate into further price appreciation as the company delivers on its guidance and navigates the usual project and regulatory risks in its industry.

More news and analyses on Bachem stock